Novel Anti Bacterial Drug
The Invention Two non-toxic short peptides were conjugated to form a novel drug candidate. One of the peptides is a polymyxin-B or polymyxin-E analog (PMBN or PMEN, respectively) while the other is an immune cell chemotactic peptide (fMLF). The resultant new drug candidates (PMBN-fMLF or PMEN-fMLF) exhibit dual antimicrobial activities: it binds specifically to gram negative bacteria, thus enhancing penetration of antibiotics into the bacteria and at the same time it promotes bacterial killing by blood phagocytes. The Need Bacteremic infections (when bacteria enter the blood stream), caused by bacteria and by Gram-negative bacilli in particular, constitute one of the major infectious disease problems in modern medicine. Antibiotic treatment is often administered too late, usually when symptoms appear, and before bacterial sensitivity to antibiotics is determined. The mortality rate due to bacterial is thus very high. Potential Applications Co –administration with antibiotics in the Treatment of septicemia and bacteremia and possibly in the treatment of other Gram Negative infections. Advantages Rapid and effective destruction of bacteria via dual complementary killing mechanisms. Development of resistance is not anticipated owing to its novel mode of action. Stage PMBN-fMLF was found to be active on a large number of clinical isolates. In vivo experiments in mice showed protection against Klebsiella pneumoniae following treatment with the drug. LD50 value of PMBN-fMLF is ~3 fold lower then polymyxin-B.PMEN-fMLF exhibited potent in vitro and in-vivo anti bacterial activity with a ~10 fold decrease in LD50, when compared to polymyxin-E
Patent Pending- US, Canada, Europe, Australia, Israel
Inventor(s): Itzhak Ofek, Matityahu Fridkin
Type of Offer: Licensing
« More Pharmaceutical Patents